Citation

Lasky-Su J, Lange C. Eur. Psychiatry 2010; 25(5): 307-309.

Affiliation

Channing Laboratory, Brigham and Women's Hospital, Boston, 181, Longwood Ave., Boston, MA 02115, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA; Center for Genomic Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Copyright

(Copyright © 2010, Elsevier Publishing)

DOI

10.1016/j.eurpsy.2009.12.019

PMID

20447807

PMCID

PMC2925169

Abstract

The etiology of suicide is complex in nature with both environmental and genetic causes that are extremely diverse. This extensive heterogeneity weakens the relationship between genotype and phenotype and as a result, we face many challenges when studying the genetic etiology of suicide. We are now in the midst of a genetics revolution, where genotyping costs are decreasing and genotyping speed is increasing at a fast rate, allowing genetic association studies to genotype thousands to millions of SNPs that cover the entire human genome. As such, genome-wide association studies (GWAS) are now the norm. In this article we address several statistical challenges that occur when studying the genetic etiology of suicidality in the age of the genetics revolution. These challenges include: (1) the large number of statistical tests; (2) complex phenotypes that are difficult to quantify; and (3) modest genetic effect sizes. We address these statistical issues in the context of family-based study designs. Specifically, we discuss several statistical extensions of family-based association tests (FBATs) that work to alleviate these challenges. As our intention is to describe how statistical methodology may work to identify disease variants for suicidality, we avoid the mathematical details of the methodologies presented.

Language: en